Patents Assigned to Daiichi Pharmaceutical Co., LTD
-
Publication number: 20100076192Abstract: 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine of formula (6) or a salt thereof, is prepared by reacting 2-amino-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine of formula (2) or a salt thereof, with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound.Type: ApplicationFiled: December 4, 2009Publication date: March 25, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Nagasawa, Koji Sato, Tsutomu Yagi, Yasuo Kitani
-
Publication number: 20100069435Abstract: Provided are a technique for position-selectively introducing an amino group into a difluorobenzoic acid, a novel process for producing a quinolonecarboxylic acid derivative serving as an antibacterial agent, and intermediates in the production. The process comprises treating a compound represented by formula (6): with a base in a water-containing solvent.Type: ApplicationFiled: October 13, 2009Publication date: March 18, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: MAKOTO MUTO, YUTAKA KITAGAWA
-
Patent number: 7678919Abstract: Taxan derivatives are produced efficiently and inexpensively, which are useful as oral-administrable antitumor compounds. A compound of formula (1) (wherein R1 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group or a heterocyclic group; R2 is a hydroxyl group optionally having a protective group) is processed with an alkali metal permanganate to produce a compound of formula (2), which may be a starting material for oral-administrable antitumor compounds.Type: GrantFiled: September 25, 2008Date of Patent: March 16, 2010Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Akihiro Imura, Tatsuya Yamaguchi, Yoshihiro Takayanagi, Seishiro Uchida
-
Publication number: 20100022783Abstract: The present invention provides a VLA-4 inhibitor having high water-solubility and excellent long-term stability; i.e., sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate.Type: ApplicationFiled: October 7, 2009Publication date: January 28, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Makoto ONO, Shigeru Noguchi
-
Patent number: 7626029Abstract: Provided are a technique for position-selectively introducing an amino group into a difluorobenzoic acid, a novel process for producing a quinolonecarboxylic acid derivative serving as an antibacterial agent, and intermediates in the production. The process comprises treating a compound represented by formula (6): with a base in a water-containing solvent.Type: GrantFiled: June 18, 2004Date of Patent: December 1, 2009Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Makoto Muto, Yutaka Kitagawa
-
Patent number: 7622471Abstract: The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. Further, the present invention provides compounds represented by formula (I), salts of the compounds, and solvates or hydrates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates or hydrates.Type: GrantFiled: February 6, 2004Date of Patent: November 24, 2009Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Naoaki Kanaya, Hiroaki Ishihara, Youichi Kimura, Takashi Ishiyama, Yuichi Ochiai
-
Publication number: 20090281074Abstract: Drug compositions containing a substituted diamine compound represented by formula (1): Q1-Q2-r-N(R1)-Q3-N(R2)??(1) wherein Q3 represents the following group wherein Q5 represents an alkylene group having 4 carbon atoms, R3 represents a hydrogen atom, and R4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.Type: ApplicationFiled: October 14, 2008Publication date: November 12, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTDInventors: Toshiharu OHTA, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Outo, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Publication number: 20090270446Abstract: The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.Type: ApplicationFiled: March 6, 2009Publication date: October 29, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Publication number: 20090253726Abstract: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided.Type: ApplicationFiled: April 13, 2009Publication date: October 8, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hisashi TAKAHASHI, Hiroaki INAGAKI, Satoshi KOMORIYA, Makoto TAKEMURA, Rie MIYAUCHI
-
Publication number: 20090240066Abstract: The present invention provides intermediates needed for production of an optically active compound represented by formula (6), which enable the compound (6) to be readily synthesized in simple production steps without optical resolution, and also provides a process for producing the intermediates. A process for producing an optically active compound represented by formula (4): wherein R1 represents a protecting group for the amino group, or a salt thereof, characterized in that a reagent prepared from an titanium(IV) reagent and an alkylmetal compound is reacted with an optically active compound represented by formula (3): wherein R1 has the same meaning as defined above, if needed, in the presence of a Lewis acid.Type: ApplicationFiled: April 24, 2009Publication date: September 24, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Masao FUJITA, Yutaka KITAGAWA, Makoto MUTO
-
Publication number: 20090226936Abstract: By finding a novel tetrahydrofolate synthetase gene and a protein encoded by said gene, a method for identifying a compound which inhibits cell growth accelerating activity of said protein is provided, and a judging method, a preventing method and a treating method of colon cancer are provided. A DNA comprising a nucleotide sequence of from the 94th to 2934th positions of the nucleotide sequence of SEQ ID NO:1 of the SEQUENCE LISTING; a polynucleotide which specifically hybridizes with said DNA; a protein encoded by said DNA; a recombinant vector comprising said DNA; a transformant comprising said recombinant vector; an antibody for said protein; a method for producing said protein; a method for identifying a compound which inhibits cell growth accelerating activity possessed by said protein; a method for judging colon cancer, characterizing in that expressed amount of said DNA is measured; a kit for judging colon cancer; a preventive agent and/or therapeutic agent for colon cancer.Type: ApplicationFiled: April 8, 2009Publication date: September 10, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventor: Takeyuki SUGIURA
-
Publication number: 20090227789Abstract: The invention relates a compound represented by the formula (1): Q1-Q2-C(?O)—N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents —CO— or —SO2—, and a medicine which comprises the compound and is useful for thrombosis and embolism.Type: ApplicationFiled: May 13, 2009Publication date: September 10, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Toshiharu YOSHINO, Tsutomu NAGATA, Noriyasu HAGINOYA, Kenji YOSHIKAWA, Hideyuki KANNO, Masatoshi NAGAMOCHI
-
Patent number: 7576135Abstract: A compound represented by formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.Type: GrantFiled: December 25, 2003Date of Patent: August 18, 2009Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Patent number: 7569599Abstract: A process for producing an optically active compound represented by formula (4), or a salt thereof, wherein R1 represents a protecting group.Type: GrantFiled: September 30, 2004Date of Patent: August 4, 2009Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Masao Fujita, Yutaka Kitagawa, Makoto Muto
-
Publication number: 20090192313Abstract: 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid of formula (5) or a salt thereof, [F14] is prepared by reacting a compound of formula (6) or a salt thereof, with a trihalogenoacetyl halide in the presence of a base, followed by hydrolysis.Type: ApplicationFiled: April 6, 2009Publication date: July 30, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi NAGASAWA, Koji SATO, Tsutomu YAGI, Yasuo KITANI
-
Patent number: 7563805Abstract: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided.Type: GrantFiled: April 28, 2006Date of Patent: July 21, 2009Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hisashi Takahashi, Hiroaki Inagaki, Satoshi Komoriya, Makoto Takemura, Rie Miyauchi
-
Publication number: 20090137600Abstract: A compound having an action of suppressing platelet aggregation is provided. This compound also exhibits excellent physical properties and oral absorbability. This compound is represented by formula (Ib): Its production method is also provided.Type: ApplicationFiled: August 5, 2005Publication date: May 28, 2009Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Koji Sato, Syouko Yoshida, Tsutomu Yagi, Kenji Sakuratani
-
Patent number: 7534562Abstract: By finding a novel tetrahydrofolate synthetase gene and a protein encoded by said gene, a method for identifying a compound which inhibits cell growth accelerating activity of said protein is provided, and a judging method, a preventing method and a treating method of colon cancer are provided. A DNA comprising a nucleotide sequence of from the 94th to 2934th positions of the nucleotide sequence of SEQ ID NO:1 of the SEQUENCE LISTING; a polynucleotide which specifically hybridizes with said DNA; a protein encoded by said DNA; a recombinant vector comprising said DNA; a transformant comprising said recombinant vector; an antibody for said protein; a method for producing said protein; a method for identifying a compound which inhibits cell growth accelerating activity possessed by said protein; a method for judging colon cancer, characterizing in that expressed amount of said DNA is measured; a kit for judging colon cancer; a preventive agent and/or therapeutic agent for colon cancer.Type: GrantFiled: September 30, 2004Date of Patent: May 19, 2009Assignee: Daiichi Pharmaceutical Co., Ltd.Inventor: Takeyuki Sugiura
-
Patent number: 7531604Abstract: A phospholipid derivative, utilizable for modification of liposomes and the like, which is a copolymer containing, as essential component units, a component unit A represented by the formula (1), a component unit B represented by the formula (2A) and/or the formula (2B), and a component unit C represented by the formula (3) [R1 and R2 represent hydrogen atom or methyl group, provided that R1 and R2 do not simultaneously represent methyl group; R3 represents a divalent hydrocarbon group having 1 to 3 carbon atoms; AO represents an oxyalkylene group having 2 to 4 carbon atoms; m represents an average molar number of the added oxyalkylene groups and is a number in the range represented as 4?m?100; R4 represents hydrogen atom, a hydrocarbon group or acyl group having 1 to 20 carbon atoms; R5CO and R6CO represent an acyl group having 8 to 24 carbon atoms; R7 represents a divalent hydrocarbon group having 2 to 4 carbon atoms; and X and Y represent hydrogen atom, an alkali metal atom, ammonium or an organic ammoniumType: GrantFiled: September 30, 2003Date of Patent: May 12, 2009Assignees: NOF Corporation, Daiichi Pharmaceutical Co., Ltd.Inventors: Syunsuke Ohhashi, Kazuhiro Kubo, Chika Itoh, Tohru Yasukohchi, Hiroshi Kikuchi, Norio Suzuki, Miho Kurosawa, Hitoshi Yamauchi
-
Publication number: 20090117205Abstract: The present invention relates to a pharmaceutical solution comprising the following components (A) and (B): (A) a compound represented by the following formula (1): or a salt thereof, or a hydrate thereof; and (B) a multivalent metal compound, wherein molar ratio of the component (B) to component (A) (the multivalent compound/component (B)) is 0.01 to 0.7. A pharmaceutical solution adapted for intravascular administration containing the quinolone compound at a therapeutically sufficient amount is provided, and this solution exhibits reduced toxicity even when the multivalent metal compound were incorporated at a reduced amount.Type: ApplicationFiled: July 1, 2005Publication date: May 7, 2009Applicant: Daiichi Pharmaceutical CO., LTDInventors: Emi Yano, Hideo Kobayashi, Hiroshi Kikuchi, Yuri Yamaguchi, Toshimasa Jindo, Norihiro Nishimoto